Iptacopan

Phase 3Recruiting

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Generalized Myasthenia Gravis

Conditions

Generalized Myasthenia Gravis

Trial Timeline

Jul 31, 2024 → May 27, 2032

NCT ID

NCT06517758

About Iptacopan

Iptacopan is a phase 3 stage product being developed by Novartis for Generalized Myasthenia Gravis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06517758. Target conditions include Generalized Myasthenia Gravis.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (11)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05222412	Pre-clinical	Active	—	—	C3 Glomerulopathy (C3G)
NCT06994845	Phase 3	Recruiting	Nov 27, 2025	Jun 30, 2030	Primary Immunoglobulin A Nephropathy (IgAN)
NCT06903234	Pre-clinical	Active	Mar 31, 2025	Oct 1, 2029	Hemoglobinuria, Paroxysmal
NCT06797518	Phase 2	Recruiting	Feb 21, 2025	Nov 27, 2027	Glomerulonephritis, IGA
NCT06517758	Phase 3	Recruiting	Jul 31, 2024	May 27, 2032	Generalized Myasthenia Gravis
NCT05935215	Phase 3	Recruiting	Feb 28, 2024	Jul 19, 2029	Atypical Hemolytic Uremic Syndrome
NCT05630001	Phase 3	Completed	Apr 24, 2023	Oct 17, 2024	Paroxysmal Nocturnal Hemoglobinuria
NCT04889430	Phase 3	Active	Jan 17, 2022	Aug 13, 2026	Atypical Hemolytic Uremic Syndrome
NCT05086744	Phase 2	Terminated	Dec 21, 2021	May 17, 2024	Immune Thrombocytopenia (ITP)
NCT04747613	Phase 3	Active	Jul 27, 2021	Oct 19, 2027	Paroxysmal Nocturnal Hemoglobinuria
NCT03439839	Phase 2	Completed	Apr 9, 2018	Feb 28, 2022	Paroxysmal Nocturnal Hemoglobinuria (PNH) With Signs of Active Hemolysis

Competing Products

20 competing products in Generalized Myasthenia Gravis

See all competitors

Product	Company	Stage	Hype Score
atomoxetine + placebo	Eli Lilly	Phase 2/3	65
Satralizumab	Chugai Pharmaceutical	Phase 3	77
Perampanel	Eisai	Pre-clinical	23
Perampanel + Placebo comparator	Eisai	Phase 3	77
zonisamide	Eisai	Pre-clinical	23
Fycompa	Eisai	Pre-clinical	23
Fycompa	Eisai	Pre-clinical	23
Perampanel	Eisai	Phase 3	77
Perampanel	Eisai	Pre-clinical	23
Cenobamate	Ono Pharmaceutical	Phase 3	77
Duloxetine + Placebo	Eli Lilly	Phase 3	77
Duloxetine + Placebo	Eli Lilly	Approved	85
Ixekizumab	Eli Lilly	Approved	85
eszopiclone + eszopiclone + Placebo	Sumitomo Pharma	Phase 2	52
Usual dose treatment of Tandospirone + Comparative high dose of tandospirone treatment	Sumitomo Pharma	Approved	85
ABBV-932 + Placebo for ABBV-932 + Antidepressant Therapy (ADT)	AbbVie	Phase 2	52
Cariprazine 0.75 mg/day + Cariprazine 1.5 mg/day + Cariprazine 3.0 mg/day	AbbVie	Phase 2	52
ABBV-932 + Placebo	AbbVie	Phase 1	33
Escitalopram	AbbVie	Approved	85
Adalimumab	AbbVie	Phase 3	77

Other Products from Novartis

LCZ696Approved

zoledronic acidApproved

NateglinideApproved

TenofovirApproved

FTY720Approved